… in monitoring of patients with metastatic melanoma receiving … melanoma and reported the
clinical significance of 5SCD [… repeated every other month with monitoring of 5SCD level in …

… Their results suggest the possible monitoring efficacy of 5-S-CD in the early phase of
nivolumab … the prognosis and monitoring the effects of the nivolumab therapy in advanced MM. …

… Prognostic value of serum 5-S-Cysteinyldopa for monitoring human … Possible case for
false-positive reaction in serum 5-S-cysteinyldopa levels in a patient with malignant melanoma by …

… progression.1, 2 As the applicability of 5-S-CD in monitoring immune-checkpoint blockade
… early phase treatment progress in melanoma patients receiving nivolumab (Nivo) therapy. …

… of malignant melanoma and monitoring its treatment. [ 31 ] Other studies reported a significant
… were significantly reduced in stage IV melanoma patients who respond to chemotherapy, [ …

… has great clinical value in the progression of melanoma. … precursor metabolites 5-S-cysteinyldopa
and DHICA plus 6-… is currently used to monitor disease progression or response …

… Many studies have used colorimetric methods monitoring the production of dopachrome …
an increase in eumelanin synthesis as seen in human melanoma cells [102]. Conversely, …

… patients with stages III–IV melanoma, the prognosis is estimated using imaging studies and
serum markers such as 5-S-cysteinyldopa (5-S-CD), melanoma … prognosis and monitoring …

Background and aims With the development of novel therapies for advanced malignant
melanoma (MM), biomarkers that can accurately reflect the progression of MM are needed. …

… On day 8, the patient was switched from nivolumab to vemurafenib (1920 mg daily). … of
5-S-cysteinyldopa (207.2 nmol/L) observed on day 10 fell to 44.1 nmol/L on day 16 (normal value, …